Search | IOVS | ARVO Journals

View

Showing 1 – 4 of 4

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2021

Neovascular age-related macular degeneration (nAMD) treated with intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E): post-hoc analysis of injection intensive (I-I) requirement for patients in the ARIES study

Sebastian Wolf; Frank G Holz; Philip Hykin; Edoardo Midena; Eric H Souied; George Lambrou; Tobias Machewitz; Helmut Allmeier; Paul Mitchell

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):423. doi:

ARVO Annual Meeting Abstract June 2020

Efficacy of Intravitreal Aflibercept Treat-and-Extend Regimen Over 2 Years for Neovascular Age-Related Macular Degeneration: ARIES Study

Eric H Souied; Frank G. Holz; Philip G Hykin; Edoardo Midena; Sebastian Wolf; Helmut Allmeier; Paul Mitchell

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4210. doi:

ARVO Annual Meeting Abstract June 2020

Comparison of treat-and-extend (T&E) dosing regimens and visual outcomes in the ARIES and ALTAIR studies of intravitreal aflibercept (IVT-AFL) in neovascular age-related macular degeneration (nAMD)

Paul Mitchell; Frank G. Holz; Philip G Hykin; Edoardo Midena; Annabelle A Okada; Eric H Souied; Kanji Takahashi; Sebastian Wolf; Helmut Allmeier; George Lambrou; Thomas Schmelter; Masahito Ohji

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4219. doi:

ARVO Annual Meeting Abstract July 2019

Efficacy of Intravitreal Aflibercept Administered using Treat-and-Extend Regimen over 2 Years in Patients with Neovascular Age-Related Macular Degeneration: 1-Year ARIES Results.

Paul Mitchell; Eric H Souied; Edoardo Midena; Frank G Holz; Philip G Hykin; Sebastian Wolf; Helmut Allmeier

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):117. doi:

Advertisement